Evonik Operations Gmbh

Universiteit Gent

Perstorp Ab

Katholieke Universiteit Leuven

University of Exeter

Filip Van Immerseel

Richard Ducatelle

Stefan Pelzer

Benedikt J Sas

Tom Van De Wiele

Richard W Titball

Evy Goossens

Conrad Gerard Schwarzer

Monika Flügel

Karolien Van Driessche

Frank Thiemann

Sarah Hark

Venessa Eeckhaut

Freddy Haesebrouck

Frank Pasmans

Christophe Courtin

Florian Böhl

Bart Devreese

Lynn Vanhaecke

Fien De Meyer

Lieven Van Meulebroek

Richard Sygall

Ruth Raspoet

Griet Debyser

Sergio Paulo Fernandes Da Costa

Dorien Mot

Karen Vermeulen

Joran Verspreet

Benedikt Sas

Growth performance, health and welfare of domesticated birds such as broilers heavily depends on a well-functioning intestinal tract. Consequently, there is a high need to find biomarkers that are specific for gut damage and that are easily applicable in the field. The present disclosure describes a set of 20 specific proteins that can be quantified in fresh fecal droppings and/or intestinal content of the birds and that each specifically correlate with a damaged gut.

Intestinal and fecal biomarkers for intestinal health of poultry

The invention pertains to an in vitro method for detecting avian intestinal dysbiosis, the method comprising determining the presence and/or level of isoleucyl-arginine (CHON) or isomers thereof in avian sample material wherein the presence and/or an increased level of isoleucyl-arginine (CHON) or isomers thereof in comparison to a non-affected control is indicative for avian intestinal dysbiosis.

In vitro method for detecting avian intestinal dysbiosis

The present invention pertains to an in vitro method for detecting intestinal barrier failure in an avian population, the method comprising the following steps: a) collecting a pooled fecal sample deriving from an avian population and b) determining the amount of at least one protein marker contained in said sample; wherein the at least one protein marker comprises or consists of an acute phase protein or a functional fragment thereof, and wherein an increased amount of said at least one protein marker contained in said sample versus a reference sample indicates intestinal barrier failure.

In vitro method for detecting intestinal barrier failure in animals

The present invention relates to a method for detectinginduced diseases in animals, the method comprising: a) collecting sample material of a specific animal or of a specific group of animals at consecutive points in time; b) determining the amount of a first marker and a second marker contained in the sample material; and c) determining the ratio of the first marker to the second marker contained in the sample material; wherein the first marker comprises a polynucleotide sequence being specific for thesub-species inducing the targeted disease; and the second marker comprises a polynucleotide being specific for the species; and wherein an increase in the ratio of the first marker to the second marker in the analyzed sample material over time is an indication of the targeted disease.

Method for detectinginduced diseases in animals

The present invention relates tomutant strains and their use as a vaccine for preventinginfection, in particular in eggs.

Method of reducing egg contamination

The present invention refers to a glycerol ester composition comprising glyceryl monovalerate, for use in preventing and/or alleviating bacterial inflammation in a monogastric animal (including human) by inhibiting the adhesion of pathogenic bacteria to the intestinal lumen of said animal. The present invention also refers to a therapeutic method for promoting the renewal and growth of epithelial cells in the small intestine of a monogastric animal (including human), the method comprising the step of distributing a glycerol ester composition comprising glyceryl monovalerate to said animal.

Composition preventing bacterial inflammation in monogastric animals

The present invention refers to a glycerol ester composition comprising the reaction product obtained from reacting valeric acid and glycerol at a molar ratio of between 1:0.8 and 1:1.2, for use in reduction and/or inhibition of the growth of gram-positive, pathogenic bacteria. The present invention also refers to said glycerol ester composition for use in prevention and/or alleviation of necrotic enteritis in the gastric tract of galloanserans.

Composition inhibiting gram-positive, pathogenic bacteria

The present invention refers to the use of a glycerol ester composition of at least one short chain fatty acid for preventing and/or alleviating necrotic enteritis in the gastric tract of galloanserans. The glycerol ester composition comprises at least 75% by weight of glyceryl tributyrate, below 25% by weight of glyceryl dibutyrate and below 8% by weight of glyceryl monobutyrate. The present invention also refers to the use of the glycerol ester composition for modulating the gut flora of galloanserans.

Composition preventing necrotic enteritis in galloanserans

The present invention relates to butyrate producing bacterial strains related to the speciesto be used in the prevention and/or treatment of intestinal health problems. The present invention therefore provides methods and compositions that overcome the problems associated with the currently used methods for administering butyric acid in the treatment of intestinal health problems in humans and/or animals.

Method for alleviating intestinal problems and novel bacterial strains therefor

Growing community of inventors

Eke, Belgium

Filip Van Immerseel